HealthcareBioVie begins treatment in phase 2 trial of NE3107 for Parkinson's diseaseJan. 20, 2022 9:51 AM ETBioVie Inc. (BIVI) StockBy: Ravikash Bakolia, SA News Editor Naeblys/iStock via Getty Images BioVie (NASDAQ:BIVI) treated the first patient in a phase 2 trial assessing the potential pro-motoric impact of NE3107 in patients with Parkinson’s disease. Pateints will be treated with carbidopa/levodopa and NE3107 or placebo in the NM201 study. The company expects topline results in mid-2022. Recommended For YouMore Trending NewsSee More »About BIVI StockSymbolLast Price% Chg1D5D1M6M1Y5Y10YMarket CapPEYield (TTM)Rev Growth (YoY)Prev. CloseCompare to PeersRelated StocksSymbolLast Price% ChgBIVI--BioVie Inc.Trending AnalysisTrending News
